ZAP Surgical

Executive Summary

ZAP Surgical is a privately held medical device company headquartered in San Carlos, California, focused on revolutionizing stereotactic radiosurgery (SRS) for brain tumors and head-and-neck conditions. Its flagship product, the ZAP-X® Gyroscopic Radiosurgery® platform, is a self-shielded, gantry-free system that eliminates the need for a dedicated treatment bunker, significantly reducing capital costs and installation complexity. Unlike traditional linear accelerator-based systems, ZAP-X employs a unique gyroscopic rotation to deliver highly conformal dose distributions with sub-millimeter accuracy, potentially improving patient outcomes and workflow efficiency. The company was founded in 2014 and has since garnered attention for its innovative approach to SRS, targeting a market poised for growth as stereotactic radiosurgery becomes more widely adopted for both malignant and benign lesions. ZAP Surgical's competitive advantage lies in its lower total cost of ownership and streamlined installation, which could enable broader access to radiosurgery in community hospitals and outpatient centers. The platform has received FDA clearance and CE marking, and early clinical data suggest non-inferiority to established systems with potential dosimetric benefits. However, as a private company, financial details and adoption metrics remain limited. Key milestones for the company include expanding clinical evidence, securing reimbursement codes, and establishing commercial traction in the U.S. and international markets. With increasing emphasis on cost-effective cancer care and non-invasive treatments, ZAP Surgical is well-positioned to capture market share, though it faces competition from established players like Accuray and Elekta.

Upcoming Catalysts (preview)

• Q3 2026FDA clearance for expanded indications (e.g., lung or liver tumors)70% success
• H2 2026Announcement of a strategic partnership or distribution agreement in Asia60% success
• Q4 2026Publication of pivotal clinical trial results demonstrating non-inferiority vs. Gamma Knife75% success